Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
HilleVax, Inc. stock logo
HLVX
HilleVax
$2.05
$2.01
$1.34
$2.17
$102.79M0.77585,512 shs3.23 million shs
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
$2.34
-4.1%
$2.12
$1.15
$33.98
$113.04M-2.05876,635 shs699,712 shs
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
$6.11
-1.0%
$5.93
$3.25
$7.89
$25.60M1.4623,479 shs7,043 shs
Zura Bio Limited stock logo
ZURA
Zura Bio
$1.52
-3.2%
$1.31
$0.97
$5.07
$107.35M-0.06987,372 shs232,231 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
HilleVax, Inc. stock logo
HLVX
HilleVax
0.00%-1.91%0.00%+7.33%+29.75%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-4.10%+8.33%+21.24%+38.87%-92.33%
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
-0.97%-1.93%+6.26%+6.72%+62.50%
Zura Bio Limited stock logo
ZURA
Zura Bio
-3.18%+5.56%+38.18%+20.16%-59.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
HilleVax, Inc. stock logo
HLVX
HilleVax
1.7691 of 5 stars
1.05.00.00.01.63.31.3
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3.6257 of 5 stars
3.33.00.04.70.00.01.3
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
1.3201 of 5 stars
3.61.00.00.00.60.00.6
Zura Bio Limited stock logo
ZURA
Zura Bio
3.7299 of 5 stars
3.65.00.00.03.82.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
HilleVax, Inc. stock logo
HLVX
HilleVax
2.00
Hold$2.00-2.44% Downside
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.50
Moderate Buy$54.502,229.06% Upside
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
3.25
Buy$17.50186.42% Upside
Zura Bio Limited stock logo
ZURA
Zura Bio
3.13
Buy$14.33842.98% Upside

Current Analyst Ratings Breakdown

Latest TENX, ZURA, SAVA, and HLVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
5/9/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.00
(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
HilleVax, Inc. stock logo
HLVX
HilleVax
N/AN/AN/AN/A$3.10 per shareN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/A$3.03 per shareN/A
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
N/AN/AN/AN/A$26.99 per shareN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/A$2.27 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
HilleVax, Inc. stock logo
HLVX
HilleVax
-$147.27M-$2.15N/AN/AN/AN/A-51.86%-41.45%8/14/2025 (Estimated)
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-$24.34M-$1.50N/AN/AN/AN/A-87.72%-72.05%8/14/2025 (Estimated)
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
-$17.60M-$2.48N/AN/AN/AN/A-31.51%-30.35%8/12/2025 (Estimated)
Zura Bio Limited stock logo
ZURA
Zura Bio
-$45.39M-$0.70N/AN/AN/AN/A-42.84%-35.22%8/12/2025 (Estimated)

Latest TENX, ZURA, SAVA, and HLVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
HilleVax, Inc. stock logo
HLVX
HilleVax
-$0.14N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
-$0.50N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.19N/AN/AN/AN/AN/A
8/6/2025Q2 2025
HilleVax, Inc. stock logo
HLVX
HilleVax
-$0.14-$0.11+$0.03-$0.11N/AN/A
5/14/2025Q1 2025
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
-$0.48-$0.28+$0.20-$0.28N/AN/A
5/8/2025Q1 2025
HilleVax, Inc. stock logo
HLVX
HilleVax
-$0.37-$0.12+$0.25-$0.12N/AN/A
5/8/2025Q1 2025
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A-$0.48N/A-$0.48N/AN/A
5/8/2025Q1 2025
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.17-$0.19-$0.02-$0.19N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
HilleVax, Inc. stock logo
HLVX
HilleVax
N/AN/AN/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/AN/A
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
N/AN/AN/AN/AN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
HilleVax, Inc. stock logo
HLVX
HilleVax
N/A
25.32
25.32
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A
9.08
9.08
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
N/A
40.48
40.48
Zura Bio Limited stock logo
ZURA
Zura Bio
N/A
8.14
8.14

Institutional Ownership

CompanyInstitutional Ownership
HilleVax, Inc. stock logo
HLVX
HilleVax
86.42%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
38.05%
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
1.67%
Zura Bio Limited stock logo
ZURA
Zura Bio
61.14%

Insider Ownership

CompanyInsider Ownership
HilleVax, Inc. stock logo
HLVX
HilleVax
24.90%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.40%
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
3.14%
Zura Bio Limited stock logo
ZURA
Zura Bio
14.23%
CompanyEmployeesShares OutstandingFree FloatOptionable
HilleVax, Inc. stock logo
HLVX
HilleVax
2050.14 million37.66 millionNot Optionable
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3048.31 million47.15 millionOptionable
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
94.15 million4.02 millionNot Optionable
Zura Bio Limited stock logo
ZURA
Zura Bio
368.38 million58.65 millionOptionable

Recent News About These Companies

Zura Bio (NASDAQ:ZURA) Shares Up 7.5% - What's Next?
Zura Bio price target lowered to $3 from $5 at H.C. Wainwright
Zura Bio (ZURA) Gets a Buy from Guggenheim

New MarketBeat Followers Over Time

Media Sentiment Over Time

HilleVax stock logo

HilleVax NASDAQ:HLVX

$2.05 0.00 (0.00%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$2.10 +0.05 (+2.44%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Cassava Sciences stock logo

Cassava Sciences NASDAQ:SAVA

$2.34 -0.10 (-4.10%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$2.38 +0.04 (+1.92%)
As of 08:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Tenax Therapeutics stock logo

Tenax Therapeutics NASDAQ:TENX

$6.11 -0.06 (-0.97%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$6.00 -0.11 (-1.80%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Zura Bio stock logo

Zura Bio NASDAQ:ZURA

$1.52 -0.05 (-3.18%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$1.53 +0.01 (+0.66%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.